



# 2022 Novel Small Molecule Drug Approvals


## Oncology (5)




**Krazati, KRAS<sup>G12C</sup> inhibitor**  
(adagrasib)  
for KRAS<sup>G12C</sup> + NSCLC after at least one prior systemic therapy  
600 mg orally BID  
**MIRATI**




**Vonjo, JAK2/IRAK1 inhibitor**  
(pacritinib)  
for myelofibrosis  
200 mg orally BID  
**CTI BIOPHARMA**



**Rezlidhia, IDH1 inhibitor**  
(olutasidenib)  
for R/R AML with susceptible IDH1 mutation  
150 mg orally BID  
**RIGEL**




**Lytgobi, irreversible FGFR1-4 inhibitor**  
(futibatinib)  
for iCCA with FGFR2 rearrangements  
20 mg orally QD  
**TAIHO**




**Pluvicto, PSMA-targeted radiotherapy**  
(lutetium <sup>177</sup>Lu vipivotide tetraxetan)  
for PSMA-positive prostate cancer  
7.4 GBq (200 mCi) IV Q6W up to 6 doses  
**NOVARTIS**


## Infectious Diseases (3)




**Sunlenca, HIV-1 capsid inhibitor**  
(lenacapavir)  
for multidrug resistant HIV-1 infection  
927 mg SC Q6M after loading period  
**GILEAD**




**Vivjoa, antifungal (CYP51 inhibitor)**  
(oteseconazole)  
for RVVC in non-reproductive females  
600-150 mg oral 11 week regimen  
**MYCOVIA**




**Voquezna, K<sup>+</sup>/H<sup>+</sup>-ATPase potassium channel blocker**  
(vonoprazan\*, amoxicillin, and clarithromycin)  
for H. pylori infection  
20 mg BID for 14 days in combo  
**TAKEDA**



**Quviviq, OX1/2 dual antagonist**  
(daridorexant)  
for insomnia  
25-50 mg orally QD  
**IDORSIA**




**Ztalmy, GABAA PAM**  
(ganaxolone)  
for seizures in CDKL5 deficiency disorder  
6 mg/kg orally TID  
**MARINUS**




**Relyvrio**  
(sodium phenylbutyrate and taurursodiol\*)  
ALS  
1 g orally daily  
**AMLYX PHARMACEUTICALS**


## Other (5)




**Pyrukynd, PK activator**  
(mitapivat)  
for hemolytic anemia in PK deficiency hematology  
5 mg orally BID  
**AGIOS**




**Camzyos, myosin inhibitor**  
(mavacamten)  
for obstructive HCM cardiology  
5 mg orally QD  
**BMS**



**Omlonti, EP2 receptor agonist**  
(omidenepag isopropyl ophthalmic solution)  
for open-angle glaucoma and ocular hypertension ophthalmology  
topical, one drop in affected eye  
**SANTEN**




**Terlivaz, vasopressin receptor agonist**  
(terlipressin)  
for hepatorenal syndrome in patients with reduced kidney function hepatology  
starting dose: 0.85 mg IV Q6h on day 1-3  
**MALLINCKRODT**




**Elucirem, gadolinium-based contrast agent**  
(gadopiclenol)  
for MRI imaging of lesions with abnormal vascularity diagnostic  
0.05 mmol/kg IV infusion  
**GUERBET**


## Dermatology (3)



**Sotyktu, TYK2 allosteric inhibitor**  
(deucravacitinib)  
for moderate-to-severe plaque psoriasis  
6 mg orally QD  
**BMS**



**Cibinqo, JAK1 inhibitor**  
(abrocitinib)  
for refractory atopic dermatitis  
100 mg orally QD  
**PFIZER**



**Vtama, AhR agonist**  
(tapinarof)  
for plaque psoriasis  
1% cream topically QD  
**DERMAVANT SCIENCES**



visit [drughunters.com/2022smda](https://drughunters.com/2022smda) for more information on each drug including:

- how they were discovered
- how they work
- how they differentiate
- ...and more